\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Security CybersecurityThe European Commission has published a Recommendation on Post-Quantum Cryptography to encourage Member States to develop and implement a coordinated approach towards post-quantum cryptography.
Quantum technologies can bring many economic and societal benefits, but advances in quantum computing are expected to also make it easier for malicious actors to access sensitive data.
Post-Quantum Cryptography (PQC) is one of the solutions to continue to protect communications for the security of our citizens, societies, economies and the EU's digital single market. PQC is based on mathematical problems that are difficult even for quantum computers to solve. As a software-based solution, it is compatible with existing infrastructures in several sectors, and can thus be deployed relatively swiftly.
The recommendation will help Member States develop a consistent strategy to migrate towards more secure ways of protecting their digital infrastructures, promoting interoperability between countries, and allowing seamlessly functioning systems and services across borders.
Stakeholders planning to submit project proposals on PQC in the future should demonstrate awareness with the content of this recommendation.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
